SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to use these drugs in patients ...
Fish treated with SGLT2 inhibitors maintained healthier kidneys as they aged. Their kidneys preserved denser networks of capillaries, retained a stronger filtration barrier, and showed more stable ...
Please provide your email address to receive an email when new articles are posted on . SGLT2 inhibition may confer similar kidney and CV outcomes vs. GLP-1 receptor agonists for diabetes. Results ...
Patients with type 2 diabetes who use empagliflozin or sodium-glucose cotransporter 2 (SGLT2) inhibitors (SGLT2) long term were shown to have less kidney function loss. A poster presented at Kidney ...
A group of medications often used to treat diabetes may also help protect aging kidneys, according to a new study.
If you have IgA nephropathy (IgAN), you’ve likely heard about the importance of protecting your kidneys and slowing down the disease. In IgAN, immunoglobulin A (IgA) antibodies accumulate in the ...
A fast-aging fish is giving scientists a rare, accelerated look at how kidneys grow old—and how a common drug may slow that ...
The Brighterside of News on MSN
Fast-aging fish reveals how kidneys age and how a common drug protects them
Kidney aging rarely draws attention until something goes wrong. Over time, these organs quietly lose strength, filter less efficiently, and struggle to keep the body balanced. A new study now brings ...
Treatment with an SGLT2 inhibitor may help patients with CKD or type 2 diabetes better preserve their kidney function. In the New England Journal of Medicine trial, investigators from The EMPA-KIDNEY ...
A potential benefit of SGLT2 inhibitors in patients with type 2 diabetes (T2D) may be reduced incidence of dry eye disease, said authors of a large retrospective study. In more than 10,000 patients ...
Everyday Health on MSN
Novel targeted therapies for IgAN: What you need to know
Explore novel therapies for IgA nephropathy that target inflammation and antibody production. Learn how these advancements ...
Author: Deepak L. Bhatt, MD, MPH, MBA, Director of Mount Sinai Fuster Heart Hospital and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results